Secukinumab's price varies depending on the formulation, dosage, and the country of purchase. As of early 2024, a typical monthly supply of secukinumab, marketed as Cosentyx, can range from approximately \$5,000 to over \$7,000 USD [1]. This pricing reflects its use as a biologic medication for treating conditions such as psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis [2].
How much does a Cosentyx prescription cost?
The cost of a Cosentyx prescription is influenced by several factors. Patients often have access to manufacturer discount programs or patient assistance foundations that can reduce out-of-pocket expenses [3]. For instance, a savings card program from the manufacturer can offer eligible commercially insured patients \$0 co-pays for their first year and then a \$5 co-pay per month thereafter, subject to program terms and conditions [3]. Without such programs, the retail price can be substantial, with a 150 mg/mL prefilled syringe costing around \$6,500 to \$7,000 [4].
What factors influence the price of biologic drugs like secukinumab?
The high cost of biologic drugs like secukinumab is attributed to several factors. The research and development process for these complex medications is extremely expensive, often spanning over a decade and requiring billions of dollars. Manufacturing these drugs also involves intricate and costly processes. Furthermore, the specialized delivery systems, such as prefilled syringes or auto-injectors, add to the overall cost. The long periods of market exclusivity afforded by patents also allow manufacturers to recoup their investment and generate profit [5].
When does secukinumab's patent protection expire?
Secukinumab is protected by multiple patents. The primary patents related to the composition of matter and methods of use are expected to expire in the coming years. For instance, key patents for Cosentyx are listed to expire around 2028 or later in major markets [6]. Patent expiry dates are crucial as they pave the way for potential generic or biosimilar competition. Information on specific patent expiry dates for pharmaceutical products can be tracked through resources like DrugPatentWatch.com [6].
Are there any biosimilar versions of secukinumab available?
As of early 2024, there are no approved biosimilar versions of secukinumab available in the United States or Europe. The development and approval process for biosimilars is rigorous and requires extensive clinical data to demonstrate similarity to the reference biologic in terms of safety, efficacy, and quality [7]. The first biosimilar applications are likely to emerge after the core patents expire.
How does secukinumab compare to other psoriasis treatments in terms of cost?
Secukinumab is a biologic therapy, which generally carries a higher price tag than traditional small molecule drugs or topical treatments for psoriasis. While effective for moderate to severe cases, its cost can be a significant consideration for patients and healthcare systems. Other biologic treatments for psoriasis, such as adalimumab (Humira) and ustekinumab (Stelara), also represent substantial investments, with monthly costs often in the thousands of dollars [8]. The comparative cost-effectiveness of these treatments is an ongoing area of analysis.
What financial assistance is available for Cosentyx users?
Patients using Cosentyx may be eligible for financial assistance programs. The Novartis Patient Assistance Foundation, Inc. provides free medication to eligible uninsured or underinsured individuals who meet certain income and residency requirements [9]. Additionally, manufacturer-sponsored savings cards can significantly lower co-pays for commercially insured patients, as mentioned previously [3].
Sources:
[1] https://www.goodrx.com/cosentyx
[2] https://www.cosentyx.com/
[3] https://www.cosentyx.com/patient-support
[4] https://www.medpac.gov/
[5] https://www.drugpatentwatch.com/blog/biologic-drug-pricing-factors
[6] https://www.drugpatentwatch.com/drugs/secukinumab
[7] https://www.fda.gov/drugs/biosimilars/understanding-biosimilars
[8] https://www.psoriasis.org/treatment/psoriasis-treatment-drugs/biologics/
[9] https://www.novartis.com/patients/patient-assistance-programs